Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP632904.RAVguXeCDpjn2f6plMyRgTTPLDEkFoRGMvTR34GGczcKU130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632904.RAVguXeCDpjn2f6plMyRgTTPLDEkFoRGMvTR34GGczcKU130_provenance.
• NP688013.RAYnBNd1cJVKjixY0WgB_cbxZ6CKZINQFRFcy3VJHAc8I130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP688013.RAYnBNd1cJVKjixY0WgB_cbxZ6CKZINQFRFcy3VJHAc8I130_provenance.
• NP268240.RAqZ9asGJ2wicYcKvMLYh2p9FDBN8GhHogrI7sROjvrV4130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP268240.RAqZ9asGJ2wicYcKvMLYh2p9FDBN8GhHogrI7sROjvrV4130_provenance.
• NP403131.RAvmDayF10wEstLbMYbBOSKujfRQCDY07pl6T0DS-qb5Y130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP403131.RAvmDayF10wEstLbMYbBOSKujfRQCDY07pl6T0DS-qb5Y130_provenance.
• NP421547.RAujs-KicLOuBlH1V7oFQuGfOF7Jhy5avM0_TIK7qy7BQ130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421547.RAujs-KicLOuBlH1V7oFQuGfOF7Jhy5avM0_TIK7qy7BQ130_provenance.
• NP641409.RAtcot5NyrHWi5XWraxILaJOD4uBjOAwGOAI5GTQQWXEo130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641409.RAtcot5NyrHWi5XWraxILaJOD4uBjOAwGOAI5GTQQWXEo130_provenance.
• NP921697.RAn5OzxrWkR-HQkPzTIUawFCNZxtCyKrvrVbWzKtkpO24130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921697.RAn5OzxrWkR-HQkPzTIUawFCNZxtCyKrvrVbWzKtkpO24130_provenance.
• NP429231.RAd2VRa87fQ3fF40vYnWvgxbPzf0A0oP87I7v_mjUg6gE130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP429231.RAd2VRa87fQ3fF40vYnWvgxbPzf0A0oP87I7v_mjUg6gE130_provenance.
• NP303912.RACGTJwL6wSfI55IdtQQx9fDKXX0v1it2CKeEFg70-VCE130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP303912.RACGTJwL6wSfI55IdtQQx9fDKXX0v1it2CKeEFg70-VCE130_provenance.
• NP904779.RA8MnoEo37PdTSZt-pYK9CjjMa9hsBTNv6ToGK7TyZnSo130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904779.RA8MnoEo37PdTSZt-pYK9CjjMa9hsBTNv6ToGK7TyZnSo130_provenance.
• NP304114.RAX6bYvsG3rhPlmXKxJxs2ausvMANNM90rGG28UpcPJgY130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP304114.RAX6bYvsG3rhPlmXKxJxs2ausvMANNM90rGG28UpcPJgY130_provenance.
• NP845274.RAXYnmuXY8TShkYtNjZvAUHDmtz8dB4wij7jCVGyDQhuQ130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP845274.RAXYnmuXY8TShkYtNjZvAUHDmtz8dB4wij7jCVGyDQhuQ130_provenance.
• assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP897802.RA3Uw5gIfpaRndvtlXiO_vBC5IIfhY8O-j5toO1i_exCQ130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP897802.RA3Uw5gIfpaRndvtlXiO_vBC5IIfhY8O-j5toO1i_exCQ130_provenance.
• assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP897804.RAMG8wEgGd4iJhxbhubLTcNCmUvLdqkUO7DxsWFqyBpKM130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP897804.RAMG8wEgGd4iJhxbhubLTcNCmUvLdqkUO7DxsWFqyBpKM130_provenance.
• NP845213.RAgGjnEF1EpLDgf-2LwOZIODHiXf0xitF40s8wBUw4oEo130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP845213.RAgGjnEF1EpLDgf-2LwOZIODHiXf0xitF40s8wBUw4oEo130_provenance.
• NP897803.RArNBsWLqIkwcUsBBTKhaTz7dv-ojh5P4jin8UYkyHvAw130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP897803.RArNBsWLqIkwcUsBBTKhaTz7dv-ojh5P4jin8UYkyHvAw130_provenance.
• NP897805.RAlFcuNTNIsL74EbbdH4ys361BSGyYepC8NdUhjw8ewVw130_assertion description "[Given the existence of genes, such as p57(KIP2), which may mediate anti-inflammatory actions of glucocorticoids, we propose that repression of transactivation represents a mechanism for glucocorticoid resistance and for understanding the clinical benefit of LABAs as an add-on therapy in asthma and chronic obstructive pulmonary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP897805.RAlFcuNTNIsL74EbbdH4ys361BSGyYepC8NdUhjw8ewVw130_provenance.